Summit Therapeutics Share Discussion Threads

[hugus maximus] 14/6/2017 12:38

RNS with First Quarter Results out today.

I'm not thrilled to see yet another delay in publication of trial data. Why is the data for RDZ v FDX being withheld until next year? The trials were conducted eons ago ... some sort of attempt at justification is needed.

The worry of forever pushing back further data announcements is certainly something that I shall be expressing at the AGM. Why is this necessary?

[aim_trader] 14/6/2017 12:23

A reminder that Summit will be presenting to investors at the Proactive One2One Forum tomorrow from 6pm in Mayfair. For details and registration, click here:

[chrisatrdg] 13/6/2017 12:43

I agree waterloo01 but with regards the $22m only a proportion will hit the bottom line in the same way earlier receipts have also be deferred in part but there will still be a chunk of money being credited.

[waterloo01] 13/6/2017 12:23

The numbers should be good as they got the $22m. Hopefully an update on both RDZ and ETZ dosing.

[chrisatrdg] 13/6/2017 12:11

RNS Out today:

SUMMIT THERAPEUTICS TO REPORT FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED 30 APRIL 2017 ON 14 JUNE 2017

[football] 05/6/2017 14:00

Summit Therapeutics says new data on selective antibiotic shows potency for treatment of clostridium difficile infection
Share
13:39 05 Jun 2017
David Roblin, Summit’s president of research & development, said: "These positive preclinical data presented at ASM Microbe highlight the potency of ridinilazole against a wide range of CDI clinical isolates from patients with CDI”
Test tubes
He added: “We believe ridinilazole has the potential to be a novel, and urgently needed, front-line treatment option for this serious disease"
Summit Therapeutics PLC (LON:SUMM) (NASDAQ:SMMT) saw its shares jump 4% after the drug developer said new preclinical data on ridinilazole, a novel and selective antibiotic for the treatment of clostridium difficile infection (CDI), had been presented at ASM Microbe 2017 in New Orleans.

The AIM and Nasdaq-listed firm said the results, presented in two poster presentations at the US conference over the first five days of June, showed that ridinilazole was very active against all CDI isolates with overall minimum inhibition concentrations distributed over a very narrow range.

READ: Summit Therapeutics strengthens R&D team
David Roblin, Summit’s president of research & development, said: "These positive preclinical data presented at ASM Microbe highlight the potency of ridinilazole against a wide range of CDI clinical isolates from patients with CDI.”

He added: "Combining potency and selectivity, ridinilazole has shown positive results in clinical trials that support its potential to treat patients with CDI and reduce the rate of recurrent disease.

“It is thought that the preservation and restoration of the patient microbiome is important in reducing recurrence and ridinilazole's narrow spectrum is designed to achieve this.

“We believe ridinilazole has the potential to be a novel, and urgently needed, front-line treatment option for this serious disease.”

In early afternoon trading Summit shares were 4.1%, or 7.5p higher at 182.5p.

[chrisatrdg] 05/6/2017 13:20

Great RNS - Looking forward to opening on the NASDAQ today.Onwards & upwards also looking forward to AGM next month.

PS My small investment in Sareum is also looking good today up 13.89% also on a good RNS.

Edit: Now 8.33 %

[waterloo01] 05/6/2017 12:10

Excellent. Active against hyper virulent and other resistant strains. Next need an update of any deal to take it forward.

[waterloo01] 02/6/2017 10:03

Another large buy, this time 50,000 shares (was similar a few days ago).

[aim_trader] 01/6/2017 15:31

Summit Therapeutics will be presenting at the Proactive One2One Forum on 15th June, for more details and registration, click here:

[someuwin] 01/6/2017 14:31

Good Afternoon,

You are warmly invited to attend Proactive Investors' One2One Forum which is taking place on Thursday 15th June at the Chesterfield
Mayfair Hotel from 6pm. Presenting on the evening will be Summit Therapeutics (LON:SUMM), NetScientific (LON:NSCI) & CentralNic (LON:CNIC).

To register to attend please click on the panel to the right or reply to this email.

Summit Therapeutics (LON:SUMM - Market Cap: £108 Million)

Summit Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines. In particular Summit is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease C. difficile infection.
Summit's shares were given a re-rating by the market last year as it signed a licensing deal with US biotech Sarepta Therapeutics worth up to $522mln. The pair are collaborating on Summit's potentially breakthrough treatment for DMD.
Management will be in attendance to explain the investment proposition at Summit Therapeutics in much more detail.


Please arrive at 5:45pm to get yourself a seat and to allow for a prompt 6:00pm start. Each company has approximately 20 minutes to give a short presentation, followed by 10 minutes of Q&A.
The evening will end with a complimentary bar and canapes, giving you the opportunity to speak with the directors and other investors.

WHO SHOULD ATTEND?
These events are tailor-made for private and professional investors who have exposure to equities, particularly growth stocks - or indeed anyone who is considering putting their money to work in dynamic sectors such as mining, oil and gas, technology and drug discovery.
WHY ATTEND?
Proactive Investors provides the meeting point for investors interested in growth stocks having organised more events than any other company in the space.
+ Over 400 Proactive Investors One2One Forums have now taken place and we have been running them since 2006.
+ Each event showcases the pick of the crop from the growth sector.
+ This is your chance to meet the management of companies you are invested in or may be considering investing in.
+ This is your chance to meet and network with like-minded investors.
+ Increasingly, these events are attracting professional money managers, analysts and family offices, who join our very knowledgeable audience of private investors.
+ That’s because over the last decade, Proactive has introduced thousands of investors to some truly spectacular growth stories.

DETAILS:
DATE: Thursday 15th June 2017
TIME: 5:45pm arrival for a prompt 6:00pm start
VENUE: Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair, W1J 5EB
ROOM: Charles Suite (1st floor)
MAP: See here for map

OTHER:

REGISTER: Complimentary wine & canape reception

Click here to Register

[freemoney1] 30/5/2017 10:15

Interesting developments of Vancomycin in the US making it more potent and less prone to resistant bacteria. But fortunately for Summit the problem with C.Diff is not antibiotic potency or resistance, it is recurrence. This is explained very well by Professor Mark Wilcox, the lead in C.Diff for public health England. Watch the series of videos below :



Hopefully Summit can secure the finance to progress RDZ through phase 3 without too much dilution of the commercial value by partnering. Maybe the previous term sheets offered by big Pharma were not so good (we don’t know… corporate confidential stuff!) which were received when Summit were lacking in finance. But since the DMD deal Summit have no immediate financial concerns and can negotiate from a stronger stance now. But also I appreciate big pharma have a huge field of potential drugs and biotechs to partner and maybe antibiotics might not be top of their list… especially when many biotechs are focussed on cancer. Maybe big Pharma are not so keen, or maybe they are simply playing hard ball for the best deal. But at least we know the lead advisor to public health England is very keen and will be pushing for Ridinizole’s usage once we have a good P3 data set. Hence my hope is that Summit can retain the commercial rights as much as possible. Looking forward to financing and deal announcements this summer. GLA

[hugus maximus] 30/5/2017 08:27

This work will not compete with Summit's C Diff drug because the new research is about a non specific targeting spectrum of anti-biotic.

RZD has a USP that has nothing to do with this new work ... it takes out the infection specifically whilst not depleting the other biddies in the gut microbiom.

For example Vancomycin (which is mentioned in the press as an anti-biotic that has lost its effectiveness against some strains of bug and is the first drug to find success using this new approach .... others may also potentially use this research) ... is a blanket bomber ... it goes into battle against a wide range of bugs. RDZ specifically takes out the C Diff and doesn't touch the remaining helpful gut flora. In the case of C Diff, the infection often returns for a second or third time, and by then the gut's healthy microbiom has been destroyed by Vancomycin, (original or new version) reducing the body's overall resistance to fight back.

I do however suspect sadly many will not understand RZD's modus operandi, so this may have a short term effect on the share price .. if the price drops as a result of disinformation, it may give some another opportunity to buy cheaper shares.

EDIT ... the share price in the UK remains surprisingly strong. Perhaps institutional investors have knowledgeable scientific advice to guide them?

[chrisatrdg] 30/5/2017 05:25

Article 20/04/17

BREAKTHROUGH RESEARCH COULD RESCUE ANTIBIOTIC OF LAST RESORT



The above sounds similar to todays news on the BBC hopefully will not compete with Summits C-Diff drug.

Todays news on the BBC today may effect share price

Below related article in the Express:

Superbugs: New drug could spell end of antibiotic resistant infections

[hugus maximus] 26/5/2017 21:02

Trouble at mill .... ?

"Sarepta sells off 21% from intermediate high as FDA drags feet over request for Exondys 51 records" :

[makingmillions] 26/5/2017 11:41

Well that was my small contribution. That should get it moving.lol

[football] 26/5/2017 11:15

Looks like someone's found some small change down the back of the sofa last and decided to use it


Wonder if we'll get a holding RNS or was it just a broker trade between themselves

[makingmillions] 26/5/2017 10:59

Either way. You would have thought it might have moved the price a bit.

[waterloo01] 26/5/2017 10:26

Some trade. Not sure if a buy or a sell.

[luminoso] 26/5/2017 10:16

Gains slipped away at close. Anyone figure out the last two trades ? 103 shares sold at 170p yesterday and a million shares sold at 174p this morning. I'd like his broker!

[luminoso] 25/5/2017 18:09

nasdaq perky again. Bit of correlation with SRPT again IMO. We up, them down.

[waterloo01] 25/5/2017 16:06

Seems like a sensible approach and would certainly put pressure on completing confirmatory studies (which from the examples given it would seem some seem to just keep delaying while they continue to get paid)

[hugus maximus] 25/5/2017 14:56

Fascinating perspective Freedosh ... I seem to remember mention a while back that EZD potentially has a $100k price tag ... which suggests a comfortable pricing in the scheme of these FDA accelerated approval issues. However we also know that if the drug shows successful P2 results, Summit have adopted a much more belt and braces approach to the trials compared to Sarepta's fiasco (mentioned here) ... so any questions about it's effectiveness for accelerated approval would hopefully be easy to negate.